SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 214 filers reported holding SAGE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.73 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $619 | +15.1% | 30,071 | +113.0% | 0.01% | -25.0% |
| Q4 2022 | $538 | -100.0% | 14,116 | -79.6% | 0.01% | -77.1% |
| Q3 2022 | $2,711,000 | -41.3% | 69,233 | -51.6% | 0.04% | -38.6% |
| Q2 2022 | $4,617,000 | -18.4% | 142,955 | -16.4% | 0.06% | -20.8% |
| Q1 2022 | $5,657,000 | +144.9% | 170,910 | +227.8% | 0.07% | +132.3% |
| Q3 2021 | $2,310,000 | +33.0% | 52,134 | +70.5% | 0.03% | +63.2% |
| Q2 2021 | $1,737,000 | +460.3% | 30,580 | +637.4% | 0.02% | +280.0% |
| Q1 2021 | $310,000 | +49.8% | 4,147 | +73.2% | 0.01% | +150.0% |
| Q4 2020 | $207,000 | -85.5% | 2,395 | -89.7% | 0.00% | -92.9% |
| Q3 2020 | $1,425,000 | -9.3% | 23,310 | -38.3% | 0.03% | -31.7% |
| Q2 2020 | $1,571,000 | +152.2% | 37,786 | +1010.7% | 0.04% | +64.0% |
| Q2 2019 | $623,000 | – | 3,402 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
| Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
| Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
| BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
| TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
| Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
| RA Capital Management | 350,933 | $49,569,000 | 2.65% |
| Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
| OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |